Sr. Director, MASH​/ALD Brand Lead & Pipeline

GSK remains committed to achieving bold commercial ambitions for the future. By 2031, we aim to deliver 40 billion in annual sales, leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patients globally. Our Ahead Together strategy is centered on early intervention to prevent and alter the course of disease, thereby protecting people and supporting healthcare systems.

Our diverse portfolio consists of vaccines, specialty medicines, and general medicines.

The role serves as the commercial Brand Lead for MASH/ALD assets and as the primary U.S. commercial authority for the broader Hepatology/Immunology pipeline and portfolio. The role has end-to-end accountability for pipeline strategy from early development through launch readiness and lifecycle management. The role owns and shapes the commercial strategy for MASH/ALD assets as they progress through development toward potential commercialization.

It also owns the commercial vision and strategic framework that guide investment decisions, stage-gate recommendations, and commercialization planning for the broader Hepatology/Immunology portfolio, ensuring the U.S. customer and commercial perspective is authoritatively represented across governance forums and global decisions.

The role also builds the commercial foundation for other pipeline assets before a dedicated brand team is in place, establishing positioning hypotheses, segmentation frameworks, and go-to-market approaches. For MASH/ALD specifically, this role serves as the commercial and strategic lead for the asset today and is expected to evolve into the full Brand Lead role as the asset advances through key milestones and, if approved, toward launch.

The scope of leadership is expected to grow as commercialization planning, launch readiness, and cross-functional team leadership requirements increase.

• Serve as the commercial and Brand Lead for MASH/ALD assets, owning and shaping the commercial strategy and leading cross-functional commercial planning and launch-readiness activities as the assets progress through development toward potential commercialization.
• Own U.S. pipeline and portfolio strategy for Hepatology/Immunology assets, establishing the commercial vision and prioritization logic that guide investment and launch-readiness decisions from Phase 2 through Local Operating Company (LOC) activation.
• Define and deliver, alongside the Medicines Commercialization Team (MCT) and Integrated Brand Commercialization Teams (IBCT), U.S. market analyses, competitive assessments, and commercial assumptions, informed by Medical-owned clinical development plans, health outcomes strategies, and financial valuations for Hepatology/Immunology pipeline assets.
• Serve as the single point of accountability for U.S. commercial input at early stage-gates, representing the voice of U.S. HCPs, patients, and payers in development decisions.
• Build and own the pre-launch commercial foundation for priority Hepatology/Immunology pipeline assets, including input to the target product profile (TPP), positioning hypotheses, customer segmentation frameworks, and initial value proposition development, ensuring each brand is commercially grounded well in advance of launch.
• Deliver stage-gate recommendations to global teams for Phase 2, 2b, and 3 decisions, clearly articulating the U.S. commercial opportunity, risk, and go/no-go rationale.
• Establish and evolve a long-range portfolio vision for Hepatology/Immunology, including asset prioritization, sequencing, and strategic planning to support future pipeline opportunities.